On December 15, 2025, Erjian Aesthetics, a leading enterprise in the global medical aesthetics field under AbbVie, held the "China Innovation Cooperation Day" event in Shanghai and simultaneously released the "AbbVie China Innovation Award (Aesthetics Award)" to support Chinese medical aesthetics innovation with practical actions.

At the AiJian Aesthetics China Innovation Cooperation Day, Wang Wei, Vice President of AiJian Aesthetics and President of Asia Pacific and Middle East Africa, Qiu Hanhua, Vice President of AiJian Aesthetics and General Manager of China, Chinmay Kanuga, Senior Director of Business Development at AiJian Aesthetics, Xiao Chang, Head of Clinical Research and Development at AbbVie China, Wan Lipeng, Head of Research and Development at AiJian Aesthetics Asia Pacific, Middle East and Africa, and Wu Congyang, Head of AbbVie Ventures China, respectively introduced AiJian Aesthetics' business development strategy, AbbVie's global and China R&D system, progress in AbbVie Aesthetics' R&D pipeline, and AbbVie's venture capital strategy. Hu Qicong, Managing Director of Boston Consulting Group, also shared China as a special guest. Insight into Medical Aesthetics Innovation. This event is hosted by Wang Danni, the head of business development for the Asia Pacific region at Erjian Aesthetics.

From acquisition to innovation, Aierjian Aesthetics creates the industry with products

Today's Aierjian Aesthetics has a product pipeline covering facial aesthetics, body shaping, plastic surgery, skin care and other fields. Through a series of acquisitions, it continues to solidify its leading position in the global medical beauty field.

Throughout the global history of Erjian's aesthetics, Bao Tuo is suitable ? With Qiao Yadeng ? It has successfully demonstrated the powerful ability of Aierjian Aesthetics to transform innovative products into global brands. It can be said that both of these products have set industry benchmarks and enabled Aierjian Aesthetics to consistently rank first in global medical beauty company revenue. However, these two products did not start from scratch in the laboratory, but were built on a model of "acquisition+system empowerment".

Botox ? Through the expansion of indications across therapeutic fields, the ultra long lifecycle of botulinum toxin has been achieved from serious medical to aesthetic fields; Juv?derm ? Through long-term clinical data accumulation and innovative product matrix, the category benchmark of hyaluronic acid has been established, promoting the standardization of injection clinical practice.

In fact, the long-term layout of Eljian's aesthetics in China has shown the expectation of local innovation?Since entering China in 2009, Erjian Aesthetics has not only introduced the concept of Bao Tuo Shi ?? Juv?derm ?? Cool Sculpture ?? Sitike ? By establishing two innovation centers in Chengdu and Shanghai, promoting professional medical education and training, and establishing a digital system connecting institutions and consumers, we have further developed our products.

The success of these individual products and their long-term layout for innovation confirm that Aijian Aesthetics provides far more than just funding, but mature business operation experience, the platform and systematic services necessary to transform technology into global value.

In the past, multinational pharmaceutical companies introduced mature products developed globally into China for localized clinical trials, registration, and sales, becoming the starting point for their development in China. But in the field of biomedicine, a deeper cooperation model - multinational pharmaceutical companies deeply involved in the early research and development of Chinese domestic biotech through venture capital, incubation platforms, research and development cooperation, and integrating its innovation into the global pipeline - has become a trend.

However, in the field of medical aesthetics with stronger consumer attributes, there are few precedents for such systematic early innovation incubation. Aierjian Aesthetics held the China Innovation Cooperation Day and released the "AiBowei China Innovation Award (Aesthetics Award)", which reflects AiBowei's rigorous pharmaceutical genes and Aierjian Aesthetics' insistence on the "medical" nature of medical aesthetics. We hope to evaluate and incubate local projects with the same rigorous scientific and evidence-based standards as biopharmaceutical innovation. This innovation award will not only provide a dart laboratory service package worth 500000 RMB, but also empower the winning innovation projects at various stages through Aierjian Aesthetics.

From the perspective of the industry, this is a forward-looking judgment and strong support of a multinational medical and aesthetic giant for China's medical and aesthetic industry. The multinational medical and aesthetic giant not only actively introduces global products, but also plans to innovate in the future. By exploring and cultivating high-quality innovation projects in China's local medical and aesthetic upstream, it builds a local innovation ecology that incubates future global products.

Nowadays, Aijian Aesthetics hopes to open up this ability to shape the industry ecosystem to local innovators.

Strategic upgrade, how does Erjian Aesthetics lead the future of medical aesthetics innovation in China

In the global medical aesthetics landscape, China has risen from a consumer market to an indispensable source of innovation inspiration and strategic growth pole. The BCG Global Medical Aesthetics Market Trends report shows that the Chinese medical aesthetics market exhibits good development prospects in terms of penetration rate and growth potential. Sullivan's "Blue Book on the Development Status and Future Trends of the Medical Aesthetics Injection Product Industry in 2025" shows that by 2027, the retail market size of medical aesthetics injection products in China will reach 147 billion yuan.

In terms of medical and aesthetic application innovation and rapid iteration, local innovation also showed amazing vitality and speed. On the one hand, the innovation activity of Chinese enterprises in the field of segmented materials is remarkable, and some technologies have developed faster than the international market. At the same time, based on a keen insight into changes in market demand, the iteration speed of Chinese medical beauty innovation is also very fast, and continuous adjustment and optimization can be achieved for some specific application scenarios.

The hot market prospects and vigorous innovation vitality have brought medical beauty innovation to its own Chinese moment. At the same time as innovative opportunities emerge, local enterprises still have a certain way to go from technological breakthroughs to global standards. Many local teams have excellent laboratory skills, but there is still room for improvement in clinical trial design, data standardization, and compatibility with regulatory requirements when transforming them into products that meet global regulatory standards. They require some experience support in research and regulation.

After passing through the early stages, innovative projects sometimes face challenges in industrialization - from laboratory samples to factory mass production, there are also difficulties in process scaling up (CMC), quality management system (GMP) construction, and so on. In addition, adequate commercial preparation and full life cycle compliance planning can also help local innovation accelerate its global orientation.

Based on this, Aierjian Aesthetics sees potential opportunities and is willing to help the industry solve challenges. On the one hand, Aijian Aesthetics has a rigorous compliance system and quality standards, and as a global leader in medical beauty, Aijian Aesthetics has participated in promoting the establishment of many industry standards and norms, with rich experience; On the other hand, the integration of innovative projects into the ecosystem of Elgin aesthetics means facing "world-class standards" and gaining the opportunity to step onto the global stage.

Chinese medical beauty needs good products, but products alone are far from enough. The truly valuable project is a high-quality "differentiated" innovation based on science, with sufficient evidence to support its safety, efficacy that can be repeatedly verified, clinical data that can withstand scrutiny, risks that are controllable and manageable, and corresponding doctor training and patient education systems.

This is the deepest metaphor of the "Aijian Aesthetics China Innovation Cooperation Day": it is a "bridge" connecting Chinese innovation with a global perspective. Chinese medical beauty innovators can integrate into the world earlier with global standards, and Aijian Aesthetics hopes to empower the high-quality development of Chinese medical beauty innovation through this long-term innovation strategy.

After all, innovation is never a decision made by an individual or a company, but rather a reflection of the entire industry. It depends on how industry participants like Elgin Aesthetics influence the industry and redefine the boundaries and depth of 'collaboration'.